Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L

trialsTrialActive

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L

A phase 2 trial of Brexucabtagene autoleucel, Cyclophosphamide, Fludarabine in mantle cell lymphoma, run by Kite, A Gilead Company, active and no longer recruiting.

Also called: JKART-1

Overview Connected5

Overview

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT06253663 by Kite, A Gilead Company, with 25 participants enrolled, started 2024-03-18 and due to reach its primary completion in 2027-07. Interventions recorded: KTE-X19, Cyclophosphamide, Fludarabine. Conditions listed: Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.

Setting

A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase

Phase 2

Sponsor

Kite, A Gilead Company

Registry

Started

2024-03-18

Enrolled

25 enrolled

Connected

Similar pages

Trial
ZUMA-2
Shares Brexucabtagene autoleucel, Gilead Sciences (incl. Kite), Mantle cell lymphoma.
Trial
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
Trial
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.

cancers

Mantle cell lymphoma

drugs

ApprovedAutologous CD19 CAR-T (CD28 costimulatory domain)

Brexucabtagene autoleucel · Tecartus

ApprovedAlkylating agent (oxazaphosphorine prodrug)

Cyclophosphamide · Cytoxan / Endoxan

ApprovedPurine nucleotide analogue (antimetabolite)

Fludarabine · Fludara (historic)

companies

Gilead Sciences (incl. Kite)

Evidence strength27/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
25 enrolled+7
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · A further 160 trial acronyms added as aliases to registry… · diff · file

Sources & links

ClinicalTrials.gov NCT06253663

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Mantle cell lymphoma

Products

Brexucabtagene autoleucel
Cyclophosphamide
Fludarabine

Companies

Gilead Sciences (incl. Kite)

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06253663/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06253663.

WebMCP tools registered on this page: onco_search, onco_get_entity.